Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Carbinoxamine Stories

2013-09-04 08:31:44

MONMOUTH JUNCTION, N.J. and CHARLOTTE, N.C., Sept. 4, 2013 /PRNewswire/ -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive licensing agreement for the commercialization of Karbinal((TM)) ER (carbinoxamine maleate) Extended-release Oral Suspension 4 mg/5 ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up. Karbinal ER is expected to be...

2013-04-03 08:27:36

-Indicated for seasonal & perennial allergic rhinitis in children ages 2 and up MONMOUTH JUNCTION, N.J., April 3, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Karbinal(TM) ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine...

2011-03-09 06:30:00

MONMOUTH JUNCTION, N.J., March 9, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations....

2010-03-16 14:22:00

SILVER SPRING, Md., March 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The FDA does not anticipate a supply problem for these...

2008-06-02 15:01:11

CORAL SPRINGS, Fla., June 2 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) 4mg Tablet (Carbinoxamine Maleate 4 mg Tablet). The Company plans to launch its product immediately. Carbinoxamine Maleate 4mg Tablet is indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic...

2006-06-08 17:11:09

WASHINGTON (Reuters) - Makers of unapproved prescription cough and cold medicines containing the drug carbinoxamine must stop selling them within 30 to 90 days, U.S. regulators said on Thursday, citing concerns the drug may harm young children. Twenty-one deaths have been reported among children under age two who took carbinoxamine products, the Food and Drug Administration said. "While it is not clear that the carbinoxamine caused these deaths, FDA is concerned about the risks of...